Addition of Disease Modifying Agents to Allogeneic HCT Shows Promise in MPNs
Investigators believe that disease modifying agents may demonstrate benefit in patients with myeloproliferative neoplasms prior to allogeneic hematopoietic cell transplant.
Therapeutic Challenge Exists With Treating Accelerated Phase Myeloproliferative Neoplasms
There remains a therapeutic challenge with understanding and treating patients with accelerated myeloproliferative neoplasms.
New Targets Open Possibilities for Novel Antibodies and Cellular Therapies in CLL
As more novel therapeutic targets are discovered in patients with chronic lymphocytic leukemia, the more possibilities are presented in terms of treatment with targeted agents, small molecules, and cellular therapies.
Lower Survival Probability Observed for High-Risk Polycythemia Vera Compared With Low-Risk Disease
Patients with high-risk polycythemia vera had a worse survival probability at 4 years compared to patients with low-risk disease.
Adaptive Therapies and Novel Targets Will Play a Notable Role in the Future Treatment of Polycythemia Vera, Expert Says
Francesco Passamonti, MD, discusses the future of treatment for patients with polycythemia vera such as adaptive therapies and the utilization of novel targets.
Pirtobrutinib Yields Promising Responses in Previously Treated CLL/SLL
Patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma appeared to benefit from treatment with pirtobrutinib.
Pirtobrutinib Demonstrates Strong Response Rates for Previously Treated CLL/SLL
Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.
Despite Improved Survival Rates in T-ALL, Investigators Seek Further Improvements Through Immunotherapeutics
The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.
2 Clarke Drive Cranbury, NJ 08512